Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
These included CT-996, a once-daily oral small-molecule oral GLP-1 receptor agonist, in Phase I, for treating obesity in patients with and without Type 2 diabetes, as well as two injectable clinical drug candidates: CT-388, a once-weekly subcutaneous injectable in Phase II, for treating obesity in patients with and without Type 2 diabetes, and CT-868, a once-daily subcutaneous injectable, in Phase II, for treating Type 1 diabetes patients with overweight or obesity
The nanomaterials can enhance the therapeutic effect of the bacterial carriers, while the bacterial carriers can enhance the therapeutic effect of the nanomaterials, thus maximizing the synergistic therapeutic effect
xCT-overexpressing cancer cells are sensitive to glutaminase inhibition because the inhibition of glutamine metabolism decreases GSH production and increases ROS production [13,121] [Figure 5B]
PMID: 194 StengerTDMillerJS
The incubation period with the dye solution was 1 h for all samples
US$ 23.11
US$ 22.73
US$ 29.90
